Replimune Group Inc [REPL] stock prices are up 1.54% to $10.53 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The REPL shares have gain 3.54% over the last week, with a monthly amount glided 11.43%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on August 28, 2024, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $17. On November 19, 2021, Piper Sandler initiated with a Overweight rating and assigned a price target of $52 on the stock. BTIG Research initiated its recommendation with a Buy and recommended $60 as its price target on November 17, 2020. Jefferies started tracking with a Buy rating for this stock on November 02, 2020, and assigned it a price target of $67. In a note dated October 15, 2020, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $25 to $54.
The stock price of Replimune Group Inc [REPL] has been fluctuating between $4.92 and $20.18 over the past year. Currently, Wall Street analysts expect the stock to reach $24.2 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $10.53 at the most recent close of the market. An investor can expect a potential return of 129.82% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -58.62%, Pretax Profit Margin comes in at -54.49%, and Net Profit Margin reading is -54.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.52 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.11 points at the first support level, and at 9.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.99, and for the 2nd resistance point, it is at 11.45.
Ratios To Look Out For
It’s worth pointing out that Replimune Group Inc [NASDAQ:REPL]’s Current Ratio is 13.46. As well, the Quick Ratio is 13.46, while the Cash Ratio is 4.25.
Transactions by insiders
Recent insider trading involved Hill Emily Luisa, Chief Financial Officer, that happened on Aug 16 ’24 when 8938.0 shares were sold. Chief Medical Officer, Xynos Konstantinos completed a deal on Jun 07 ’24 to sell 15881.0 shares. Meanwhile, Chief Commercial Officer Sarchi Christopher sold 2218.0 shares on May 16 ’24.
